Lilly enrols first COVID-19 patient in Phase III study to test baricitinib
A Phase III trial has been launched to study whether baricitinib, an oral JAK1/JAK2 inhibitor, is effective at combatting COVID-19 in hospitalised patients.
List view / Grid view
News
EDQM to provide COVID-19 vaccine developers free access to quality standards
The EDQM and European Pharmacopoeia have decided to share Ph. Eur. quality standards for COVID-19 vaccine developers to support their research.
Dexamethasone could reduce COVID-19 patient death risk by one-third, study shows
A clinical trial has shown that an inexpensive steroid called dexamethasone could prevent death in one out of eight ventilated COVID-19 patients and one out of 25 patients receiving oxygen only.
TRV027 to be tested as COVID-19 illness treatment in clinical trial
A clinical trial is set to investigate whether a molecule known as TRV027 is effective at preventing lung damage and the formation of blood clots in COVID-19 patients.
NICE recommends Rozlytrek (entrectinib) as treatment for NSCLC
After three clinical trials showing its efficacy, NICE has recommended Rozlytrek (entrectinib) as treatment for non-small cell lung cancer (NSCLC).
FDA revokes emergency use authorisation for chloroquine and hydroxychloroquine as COVID-19 treatments
Following ongoing analysis and emerging scientific data, the FDA has taken away its emergency use authorisation for chloroquine and hydroxychloroquine, finding they are unlikely to be effective as COVID-19 treatments.
Trial for new ibuprofen formulation as COVID-19 treatment launched in UK
A unique formulation of ibuprofen is being tested as a treatment for severe acute respiratory distress syndrome (ARDS), a symptom of COVID-19.
UK CMA disqualifies pharma company director after breaking competition law
A pharmaceutical company director is now banned from holding a director role at any UK company for the next five years after making illegal arrangements.
New HIV drug formulation approved by FDA to treat paediatric patients
The FDA has approved Tivicay (dolutegravir) and Tivicay PD (dolutegravir) dispersible tablets to treat HIV in children at least four weeks old and weighing at least 3kg.
Researchers synthesise red blood cells with ability to deliver drugs
Artificial red blood cells have been created by researchers which can be used as normal cells or to carry drugs around the body.
Study suggests current drug shortages in US will be worsened by COVID-19 pandemic
A newly released paper has revealed that the shortages of medications in the US at present will be increased further due to the COVID-19 outbreak.
WHO stresses need for new treatments to reduce antimicrobial resistance
Following a record level of data collated by WHO, the organisation has emphasised that new antibiotics need to be developed to tackle the rise of global antimicrobial resistance.
Global excipients market predicted to grow at CAGR of six percent
New research has shown that the global pharmaceutical excipients market is expected to grow from $6,496.05 million in 2018 to $9,847.12 million in 2025.
J&J accelerates clinical trial of investigational COVID-19 vaccine
The investigational SARS-CoV-2 vaccine developed by J&J is now due to start its Phase I/IIa clinical trial at the end of July.
Microneedle system developed to deliver mesenchymal stem cells
A group of researchers has developed a microneedle delivery system for mesenchymal stem cells, which showed success in mice skin wound models.
